Navigation Links
Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Date:8/20/2007

aring two dose levels of OxyADF Tablets to placebo. Study medication will be administered to patients every six hours for 48 hours following the onset of moderate to severe pain following bunionectomy surgery. Study 105 is targeted to enroll 135 patients per arm (approximately 405 patients in total). As previously announced, the Company executed a Clinical Trial Development Agreement with a leading Contract Research Organization and commenced preliminary Study 105 start-up activities. However, initiation of patient enrollment in Study 105 remained dependent upon the availability of adequate funding. Now that new funding has been secured, the Company intends to proceed with patient enrollment in Study 105. The Company believes the completion of Study 105 is the critical time and events path to a 505(b)(2) NDA submission for OxyADF Tablets.

About Acura Pharmaceuticals, Inc.

Acura Pharmaceuticals, Inc. is a specialty pharmaceutical company engaged in research, development and manufacture of innovative Aversion(R) (abuse deterrent) Technology and related product candidates.

Forward Looking Statements

This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from the Company's expectations and projections. The most significant of such risks and uncertainties include, but are not limited to, the Company's ability to secure additional financing to fund operations, the Company's ability to enter into contractual arrangements with qualified pharmaceutical partners to license, develop and commercialize the Company's technology and product candidates, the Company's ability to avoid infringement of patents, trademarks and other proprietary rights or trade secrets of third parties, and the Company
'/>"/>

SOURCE Acura Pharmaceuticals, Inc.

Copyright©2007 PR Newswire.

Page: 1 2 3

Related medicine technology :

1. Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple Myeloma and Waldenstroms Macroglobulinemia
2. Keryx Biopharmaceuticals, Inc. Announces Poster Presentations Highlighting Mechanism of Action and Clinical Activity of Sulonex(TM) (sulodexide oral gelcap) at the Upcoming American Diabetes Association 67th Scientific Sessions in Chicago, Illinois
3. Molecular Insight Pharmaceuticals, Inc. Presents Preclinical Data on Molecular Imaging Pharmaceutical for Prostate Cancer
4. Molecular Insight Pharmaceuticals, Inc. Presents Preclinical Data at Society Of Nuclear Medicine 2007 Annual Meeting
5. CytRx Announces RNAi Delivery Nanoparticle Technology Exclusively Licensed to Subsidiary, RXi Pharmaceuticals, Described in Peer-Reviewed Journal
6. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
7. Advanced Life Sciences Announces Supplemental Efficacy Data from First Pivotal Phase 3 Pneumonia Clinical Trial
8. Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkins Lymphoma
9. Accentia Biopharmaceuticals Announces Favorable Interim Blinded Data on SinuNase in Its Fast-Tracked Pivotal Phase 3 Clinical Trial for Chronic Sinusitis
10. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
11. Cethromycin Achieves Primary Endpoint in Pivotal Phase 3 Pneumonia Clinical Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... July 24, 2014  IRIDEX Corporation (NASDAQ: ... second quarter 2014 financial results after the market closes ... with the release, the Company will host a conference ... Eastern Time on Thursday, July 31, 2014 ... other business developments. Interested parties may access ...
(Date:7/24/2014)... July 24, 2014 Omnicell, Inc. (NASDAQ: ... medication and supply management solutions and analytics software ... July 31, to discuss the Company,s Second Quarter ... Quarter 2014 earnings conference call and webcastWhen: ... Randall Lipps, chairman, president and chief executive officer ...
(Date:7/24/2014)... -- IGI Laboratories, Inc. (NYSE MKT: IG), a New Jersey based ... results for the second quarter ended June 30, 2014. ... of $6.5 million in the second quarter of 2014, an ... , Total revenues of $13.3 million for the six months ... same period in 2013 , Total revenues generated from ...
Breaking Medicine Technology:Omnicell to Release Second Quarter 2014 Earnings Results on July 31 2IGI Laboratories Announces Second Quarter 2014 Results 2IGI Laboratories Announces Second Quarter 2014 Results 3IGI Laboratories Announces Second Quarter 2014 Results 4IGI Laboratories Announces Second Quarter 2014 Results 5IGI Laboratories Announces Second Quarter 2014 Results 6IGI Laboratories Announces Second Quarter 2014 Results 7
... MicroCHIPS, Inc., a developer of innovative drug delivery ... Office and Trademark Office has granted U.S. Patent No. ... This patent in conjunction with U.S. Patent No. 7,070,590 ... reservoir-based medical devices used for implantable drug delivery systems. ...
... Promidian, a management consulting firm focused on ... survey findings about the increasing interest in the ... that is rapidly gaining nationwide attention for its ... care—while reducing costs. The Promidian ...
Cached Medicine Technology:MicroCHIPS Announces 35th U.S. Patent for Microreservoir-Based Drug Delivery Systems 2Promidian Survey Finds Growing Support for Patient-Centered Medical Home 2
(Date:7/27/2014)... 2014 This is a professional ... Dutasteride (CAS 164656-23-9) industry. The report firstly reviews ... its classification, application and manufacturing technology. The report ... Dutasteride (CAS 164656-23-9) listing their product specification, capacity, ... report further analyzes quantitatively 2009-2014 global and China’s ...
(Date:7/27/2014)... July 27, 2014 The report ... in Aviation - Market Analysis (Commercial Aviation And ... Pneumatic, Hydraulic, Mechanical) - Forecasts 2014 - 2019." ... are expected to shape the market during the ... and technology trends that are currently prevailing in ...
(Date:7/27/2014)... News) -- Couples aren,t more likely to get divorced ... new research finds. The study only looks at ... play a direct role in affecting whether couples stay ... speak against fears that women,s growing educational advantage over ... Schwartz, lead author of the study, said in an ...
(Date:7/27/2014)... July 27, 2014 Alta Resources ... outsourcing (BPO) for Fortune 500 brands, announced today that ... its locations in Wisconsin, California, Florida and the Philippines. ... several health-insurance clients, which have seasonal ramp-ups that require ... (AEP), November 2014 through February 2015. As more consumers ...
(Date:7/27/2014)... 27, 2014 The Institute of Safe ... adverse events such as Xarelto bleeding side-effects reported after ... out numbered the complaints filed for its competitor Pradaxa, ... for Xarelto increased to nearly 1 million prescriptions per ... early 2012, the ISMP noted in its latest issue ...
Breaking Medicine News(10 mins):Health News:Global and Chinese Dutasteride Industry (CAS 164656-23-9) 2019 Forecasts in New Research Report at ReportsnReports.com 2Health News:Global and Chinese Dutasteride Industry (CAS 164656-23-9) 2019 Forecasts in New Research Report at ReportsnReports.com 3Health News:Global and Chinese Dutasteride Industry (CAS 164656-23-9) 2019 Forecasts in New Research Report at ReportsnReports.com 4Health News:Actuator Systems Market in Aviation Estimated to Reach $3,839.74 Million by 2019 - New Report by MarketsandMarkets 2Health News:Actuator Systems Market in Aviation Estimated to Reach $3,839.74 Million by 2019 - New Report by MarketsandMarkets 3Health News:Actuator Systems Market in Aviation Estimated to Reach $3,839.74 Million by 2019 - New Report by MarketsandMarkets 4Health News:Wives' Higher Education May Not Affect Divorce Rate 2Health News:Alta Resources to Fill Approximately 2,500 Positions 2Health News:Alta Resources to Fill Approximately 2,500 Positions 3Health News:Xarelto Lawsuit News: Report Finds Adverse Events For Xarelto Bleeding Side-Effects Outnumber Those For Pradaxa 2Health News:Xarelto Lawsuit News: Report Finds Adverse Events For Xarelto Bleeding Side-Effects Outnumber Those For Pradaxa 3Health News:Xarelto Lawsuit News: Report Finds Adverse Events For Xarelto Bleeding Side-Effects Outnumber Those For Pradaxa 4Health News:Xarelto Lawsuit News: Report Finds Adverse Events For Xarelto Bleeding Side-Effects Outnumber Those For Pradaxa 5
... chronic hepatitis C are at risk of suffering from ... weeks from commencement of treatment, says the researchers in a ... Science (IOVS)in the January 2007 issue. ,Researchers from ... in diameter of blood vessels and the velocity of ...
... that suggests a link between a particular gene named ... journal, Neurobiology of Aging, published the results of the ... implicated in causing Alzheimer’s disease. ,This research now ... raises the possibility that occurrence of herpes infection earlier ...
... have to prescribe medicines by their generic names instead of ... ,"We have issued a letter in this regard to all ... and dispensaries," Singh told IANS. ,The doctors ... not the brand names. Failure to do so would call ...
... Leading pharmaceutical company Lupin Ltd has received tentative approval ... its generic drug Sertraline Hydrochloride for// treatment of major ... will be the AB-rated generic equivalent of Pfizer's Zoloft ... ,"The company intends to launch the generic (drug) ...
... were thought to be far cleaner and healthier as compared ... not true- inner cities are a haven// for unhealthy habits ... smoking and disease rates and dietary habits to understand the ... that towns such as Merthyr Tydfil in Wales happened to ...
... be used for 15 minutes before sleeping to treat insomnia ... based company Helicor, is under clinical trial on 100 patients ... heartbeat by regulated deep breathing, said the online edition of ... several other conditions including anxiety and panic attacks, is said ...
Cached Medicine News:Health News:Herpes Simplex and Alzheimer’s Disease Linked to Single Gen 2Health News:Herpes Simplex and Alzheimer’s Disease Linked to Single Gen 3Health News:Herpes Simplex and Alzheimer’s Disease Linked to Single Gen 4
Liquichek Hematology Control (A) is an assayed hematology control for evaluating the performance of Abbott Cell-Dyn 1600, 1700, 3000, 3500 and 3700 analyzers with 5-part differential technology....
... Liquichek ToRCH Plus Control ... used to monitor the performance ... serology instruments and assays. A ... control allow you to monitor ...
Liquichek™ Ethanol/Ammonia Control is a liquid product used to monitor ethanol and ammonia test procedures in the clinical laboratory....
Liquid Assayed and Unassayed Multiqual Controls are comprehensive, liquid, human serum based chemistry controls, available in three levels....
Medicine Products: